FIELD: chemistry.
SUBSTANCE: invention relates to novel GLP-1 compounds with prolonged effect and therapeutic application thereof.
EFFECT: improved method.
26 cl, 22 ex
Title | Year | Author | Number |
---|---|---|---|
GLUCAGON-LIKE PEPTIDE-1 (GLP-1) DERIVATIVES | 2004 |
|
RU2401276C2 |
DIPEPTIDE, CONTAINING NONPROTEINOGENIC AMINO ACID | 2012 |
|
RU2643515C2 |
SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT AND LUBRICANT | 2019 |
|
RU2807183C2 |
SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT | 2019 |
|
RU2804318C2 |
SOLID COMPOSITIONS CONTAINING AGONIST TO GLP AND SALT OF N-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | 2011 |
|
RU2600440C2 |
GLP-1 PEPTIDES COMPOSITIONS AND THEIR PRODUCTION | 2013 |
|
RU2641198C2 |
DOUBLE-ACYLATED GLP-1 DERIVATIVES | 2010 |
|
RU2559540C2 |
ACYLATED DERIVATIVE OF GLP-1 | 2019 |
|
RU2773242C2 |
ORAL DOSING OF GLUCAGON-LIKE PEPTIDE-1 COMPOUNDS | 2014 |
|
RU2671406C2 |
STABLE PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-ANTAGONISTS FOR MEDICAL USE | 2014 |
|
RU2683039C2 |
Authors
Dates
2011-11-20—Published
2006-03-20—Filed